Physician profile
Roger A Hiser
NPI 1528064581
$5,606.23
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,270 · 2020: $256 · 2021: $135 · 2022: $775 · 2023: $1,690 · 2024: $1,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,161 · Education: $8.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,161.23 |
| Education | $8.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,100.47 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $622.76 | 2019-2024 | |
| Abbvie INC. | $554.53 | 2019-2024 | |
| Lilly USA, LLC | $531.67 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $357.77 | 2019-2024 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $321.13 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $291.07 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.75 | 2019-2024 | Jardiance |
| Dexcom, INC. | $191.61 | 2022-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $159.05 | 2019-2023 | |
| Astellas Pharma US INC | $157.80 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $156.58 | 2019-2023 | Xarelto |
| Abbott Laboratories | $152.54 | 2019-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $119.66 | 2019 | |
| Sumitomo Pharma America, INC. | $104.86 | 2023-2024 | Gemtesa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $95.64 | 2023-2024 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $73.81 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $59.67 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $53.01 | 2024 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.58 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $48.29 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.97 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.90 | 2023 | Rexulti |
| Bausch Health US, LLC | $19.98 | 2019 | |
| Medtronic, INC. | $18.95 | 2024 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $18.45 | 2023 | Belsomra |
| Shire North American Group INC | $18.32 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.65 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.05 | 2022 | |
| Lundbeck LLC | $14.14 | 2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $13.83 | 2023 | Qelbree |
| Allergan, INC. | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Hiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.